New methods of regenerative medicine have made clinical progress in the treatment of isoemia heart disease

Myocardial infarction is a serious threat to human health heart disease, although timely drug treatment, coronary artery intervention therapy, coronary artery bypass transplantation and other treatment methods can save the lives of some patients with myocardial infarction, but for serious stale myocardial injury, there is still no effective treatment.Dai Jianwu's regenerative medicine team from the Institute of Genetics and Developmental Biology of the Chinese Academy of Sciences, in collaboration with Professor Wang Dongjin of Nanjing Gulou Hospital, carried out the first international clinical study on the treatment of ischemic heart disease in combination with stem cell transplantation of injectable collagen stent materials. On September 10, the team published their findings online in the journal Journal of the American Medical Association: Starting in March 2016, aging heart attack patients were recruited through a one-year follow-up of 44 subjects in the group. The results showed that cell and material transplantation was safe, the combined stem cell transplantation of glue raw materials significantly reduced the volume of heart infarction in patients after one year, and the quality of life and heart rating of patients improved, especially in patients with preoperative conditions (heart shot fraction less than 40%).Dai Jianwu introduced that stem cells have the potential of self-renewal and differentiation, as well as strong nutrition and secretion function, stem cell transplantation is a hot research topic in the field of heart muscle regeneration, but its therapeutic effect is still controversial. Some studies have shown that stem cell transplantation is easy to spread, it is difficult to plant in the damage site to survive, affecting the effectiveness of treatment. Therefore, how to promote the planting of stem cells in the heart muscle injury site is the key problem that stem cell therapy needs to solve.Dai Jianwu led the research team for a long time engaged in the research of functional biological materials of regenerative medicine, after many years of research successfully developed a good biocompitive collagen stent can be used for intramyal injection, can provide stable extracellular substation support for cells, injection into damaged cardiomyopathy tissue can effectively limit the spread of cells from the damaged site, help reshaping myocardial regeneration to repair the microenn environment. At present, this material has completed product standardization research, and access to China Food and Drug Inspection Research Institute and other authoritative institutions of product technical requirements certification, biosecurity testing, immuno evaluation, virus inactivation testing and other reports, to meet the quality standards of clinical implantable medical devices.Dai Jianwu team and Nanjing Gulou Hospital Wang Dongjin team to carry out preclinical large animal experiments to test the safety and effectiveness of materials and cell transplantation. On the basis of the clear safety and effectiveness assessment of animal experiments, the team further developed clinical trial programs, completed ethical review and international clinical research registration, and conducted randomized controlled clinical studies of injectable plastic raw materials combined with umbilical cord-filled stem cells to treat isohemic heart disease with the support of the Chinese Academy of Sciences" Strategic Pilot Technology Project and Key Deployment Project "Tissue Organ Regeneration and Damage Repair".The basic entry criteria for this clinical study were obsolete heart attack patients with heart function less than 45% who needed bridge surgery. After more than three years of efforts, the study of 50 patients in the group, completed 44 patients after surgery 1 year follow-up, the results show that cell and material transplant safety is good, in malignant events (death, tumor, persistent titration, heart failure re-hospitalization, heart rhythm, etc.) incidence, biochemical indicators, immune indicators and other aspects of the control group there is no significant difference. Compared to the control group, the combined stem cell transplantation of glue raw materials significantly reduced the volume of heart infarction in patients after one year, and improved the quality of life and heart rating of patients. The effect was particularly pronounced in patients with preoperative cardiac blood test scores of less than 40 per cent: the average heart shot score increased by 9.35 per cent in the year after the bridge and stem cell and glue injections, while the control group increased to 6.59 per cent (bridge surgery joint stem cell transplantation group) and 3.62 per cent (separate bridge surgery group).This is the first international clinical study of injectable stent material in combination with stem cell transplantation to treat isothermic heart disease, and this study proves for the first time the clinical safety and feasibility of injectable material combined stem cells for heart disease treatment, and shows good application prospects, laying the foundation for subsequent large-sample clinical trials. (Bright Daily)